Resmetirom is a new promising agent against MASLD; it is an oral drug, which is liver-directed, and is a thyroid hormone receptor beta (THR-β)-selective agonist in development for the treatment of hepatic steatosis with liver fibrosis. Here, THRB is linked to metabolic dysfunction-associated steatotic liver disease.